AK157D1

AK157D1 is an investigational next-generation antibody-drug conjugate (ADC) developed by Akeso, Inc. (AkesoBio) as part of its proprietary 'ADC 2.0' pipeline. This platform is designed to enhance the therapeutic index of ADCs by utilizing novel linker-payload technologies aimed at improving systemic stability and increasing potency within the tumor microenvironment. While the specific biological target and cytotoxic payload of AK157D1 remain undisclosed as of mid-2026, the asset represents Akeso's strategic expansion into advanced ADC modalities to address the safety and efficacy limitations associated with earlier-generation conjugates. It is currently in the early stages of clinical development for the treatment of advanced solid tumors.